Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections
Objectives Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clinical trials. Its safety in routine practice might be different.Methods We retrospectively analyzed the infection complications in an unselected cohort of patients treated with bendamustine over...
Main Authors: | Tony K.Y. Wu, Karen H.K. Tang, Yu-Yan Hwang, Thomas S.Y. Chan, Eric Tse, Yok-Lam Kwong |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2072065 |
Similar Items
-
Apoptotic colopathy following bendamustine therapy
by: Vincent Czerwinski, et al.
Published: (2023-11-01) -
Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
by: Jessica Stokes, et al.
Published: (2021-04-01) -
Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01) -
Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient
by: Gabriele Magliano, et al.
Published: (2021-08-01) -
The role of cytomegalovirus in the development of opportunistic infections
by: Elena Cirjau, et al.
Published: (2019-03-01)